Uppsala 23rd  January 2018


Nanexa gather Advisory Board in Oncology

Nanexa has identified the oncology area as particularly interesting and aims at making a direction decision for its own product project in the first half of 2018. In order to mark out Nanexa’s own product project, the Company has gathered an Advisory Board with deep knowledge in the field of oncology.

The group, consisting of four external members and a number of Nanexa members, will identify relevant indications and active substances that match key medical needs in the oncology field, where Nanexa’s drug delivery platform PharmaShell® offers new treatment benefits. Recommendations from this group, along with market data for relevant indications, will lead to decisions on product projects based on PharmaShell®.


The external members of the Nanexa Advisory Board are:


Jan-Olof Fernberg, Associate Professor of Clinical Oncology

Matthias Löhr, Professor and Chief Physician, Unit for Surgery, Karolinska Universitetssjukhuset

Bengt Westermark, Professor, Department of Immunology, Genetics and Pathology, Uppsala University

Jeffrey Yachnin, Associate Professor, Clinical Examination Unit, Oncology Clinic, Karolinska Universitetssjukhuset


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se